Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9128273 | 0.92 | LMNA (0.64) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL14059325 | 0.91 | TDP1 (0.61) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL537056 | 0.87 | LMNA (0.70) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL1655944 | 0.87 | TDP1 (0.73) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL2580214 | 0.87 | TDP1 (0.66) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL15341181 | 0.85 | TDP1 (0.74) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL26451268 | 0.84 | TDP1 (0.66) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL23812446 | 0.83 | TDP1 (0.60) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL8059715 | 0.83 | LMNA (0.64) | TDP1LMNAKMT2ASLC6A2SLC6A3 | |
| SCHEMBL6832242 | 0.83 | TDP1 (0.67) | TDP1LMNAKMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-5468897-A | Bi-aromatic esters, a process for their preparation and their use in human or veterinary medicine and in cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-11-21 | — | — | US | disclosed |
| US-5332856-A | Treatment of a dermatologic, rheumatismal, respiratory or ophthalmologic ailment | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5200550-A | Administering for dermatologic, rheumatismal, respiratory or ophthalomologic disorders | CENTRE INTERNATIONAL DE RECHERCES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1993-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | TDP1 4305/4885LMNA 3585/4885KMT2A 3382/4885 |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | TDP1 2818/4885LMNA 1913/4885KMT2A 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.